Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Bryan, Downie"'
Autor:
Peter C. Taylor, Bryan Downie, Ling Han, Rachael Hawtin, Angie Hertz, Robert J. Moots, Tsutomu Takeuchi
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1383-1392 (2024)
Abstract Introduction High baseline neutrophil-to-lymphocyte ratio (NLR) in rheumatoid arthritis (RA) has been associated with positive responses to biologic tumor necrosis factor inhibition and negative responses to conventional synthetic disease-mo
Externí odkaz:
https://doaj.org/article/8791698927c94580b5379123fd399380
Autor:
Nicholas T. Funderburg, Susie S. Y. Huang, Calvin Cohen, Kate Ailstock, Morgan Cummings, Jean C. Lee, Brenda Ng, Kirsten White, Jeffrey J. Wallin, Bryan Downie, Grace A. McComsey
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundHeightened levels of inflammatory markers are linked to increased morbidity/mortality in people with HIV (PWH) and often remain elevated after virologic suppression by antiretroviral therapy (ART). As new combinations of ART become availabl
Externí odkaz:
https://doaj.org/article/4c70560a0cfa454db03d0fbb5ef429d1
Autor:
Jeffrey R. Curtis, Paul Emery, Bryan Downie, Yan Zhong, Jinfeng Liu, Ling Han, Rachael E. Hawtin, Gerd Rüdiger Burmester
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 1, Pp 177-189 (2023)
Abstract Objectives To assess cigarette smoking’s effects on efficacy of the preferential Janus kinase (JAK) 1 inhibitor filgotinib and drug persistence in patients with rheumatoid arthritis (RA). Methods Efficacy in non-smokers, former smokers, an
Externí odkaz:
https://doaj.org/article/e8bc03cbee46488dacc4d9c58186f5de
Autor:
Yoshiya Tanaka, Peter C. Taylor, Emon Elboudwarej, Angie Hertz, Xiaorong Shao, Vladislav A. Malkov, Hironori Matsushima, Kahaku Emoto, Bryan Downie, Tsutomu Takeuchi
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 5, Pp 1335-1348 (2023)
Abstract Introduction Our aim was to evaluate protein biomarker changes related to the administration of filgotinib, a Janus kinase (JAK) 1 preferential inhibitor, in patients with moderately to severely active rheumatoid arthritis (RA) with inadequa
Externí odkaz:
https://doaj.org/article/42bef335c7494c6c9933325ae15de018
Autor:
David Z. Pan, Pamela M. Odorizzi, Andre Schoenichen, Mazin Abdelghany, Shuguang Chen, Anu Osinusi, Scott D. Patterson, Bryan Downie, Kavita Juneja, Jeffrey J. Wallin
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-6 (2023)
Pan et al. determine the impact of the antiviral remdesivir (RDV) on biomarkers associated with clinical outcomes, within a randomized, double-blind, placebo-controlled phase 3 study (PINETREE). They demonstrate that RDV-treated patients have an acce
Externí odkaz:
https://doaj.org/article/8ae67f1cda5e4070bf72742899d454ad
Autor:
Yoshiya Tanaka, Peter C. Taylor, Emon Elboudwarej, Angie Hertz, Xiaorong Shao, Vladislav A. Malkov, Hironori Matsushima, Kahaku Emoto, Bryan Downie, Tsutomu Takeuchi
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 1, Pp 223-224 (2023)
Externí odkaz:
https://doaj.org/article/b25389f148c54be1a0bd1e4e87cf6c73
Autor:
Md. Taibur Rahman, Izabela J. Swierzy, Bryan Downie, Gabriela Salinas, Martin Blume, Malcolm J. McConville, Carsten G. K. Lüder
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 11 (2021)
Toxoplasma gondii is an obligatory intracellular parasite that causes persistent infections in birds and mammals including ~30% of the world’s human population. Differentiation from proliferative and metabolically active tachyzoites to largely dorm
Externí odkaz:
https://doaj.org/article/c5e5abb9b8f842f2bf5b69645e92e298
Autor:
Ondrej Podlaha, George Wu, Bryan Downie, Raghuraman Ramamurthy, Anuj Gaggar, Mani Subramanian, Zhishen Ye, Zhaoshi Jiang
Publikováno v:
PLoS ONE, Vol 14, Iss 7, p e0220376 (2019)
Hepatitis B infection is a world-wide public health burden causing serious liver complications. Previous studies suggest that hepatitis B integration into the human genome plays a crucial role in triggering oncogenic process and may also constitutive
Externí odkaz:
https://doaj.org/article/88c92b48a1ba4cd9ab5ca1e561d030e0
Autor:
Elizabeth, Price, Michele, Bombardieri, Alan, Kivitz, Franziska, Matzkies, Oksana, Gurtovaya, Alena, Pechonkina, Wendy, Jiang, Bryan, Downie, Anubhav, Mathur, Afsaneh, Mozaffarian, Neelufar, Mozaffarian, J Eric, Gottenberg
Publikováno v:
Rheumatology. 61:4797-4808
Objective The aim of this study was to characterize the safety and efficacy of filgotinib, lanraplenib and tirabrutinib in patients with active SS. Methods This multicentre, double-blind study randomized patients with active primary or secondary SS [
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74b9dad1a67e0ad6b2078e508d4f78b2
https://doi.org/10.1093/rheumatology/keac167
https://doi.org/10.1093/rheumatology/keac167
Publikováno v:
Rheumatology. 61
Background/Aims Filgotinib (FIL), an oral janus kinase 1 (JAK1) inhibitor, has been evaluated in three Phase 3 clinical studies (FINCH 1-3) in adults with moderately-to-severely active rheumatoid arthritis (RA). Patients with RA who currently smoke (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f2a6024e7d83970b7b7e0289d29d235
https://doi.org/10.1093/rheumatology/keac133.203
https://doi.org/10.1093/rheumatology/keac133.203